Cetuximab for the Treatment of Colorectal CancerDerek J. Jonker, Malcolm J. Moore, Chris J. O’Callaghan et al.|New England Journal of Medicine|2007Cited by 1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal CancerAlan P. Venook, Charles D. Blanke, Donna Niedzwiecki et al.|JAMA|2017Cited by 891
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Kai‐Keen Shiu et al.|The Lancet Oncology|2023Cited by 614
Common Sense Oncology: outcomes that matterChristopher M. Booth, Bishal Gyawali, Manju Sengar et al.|The Lancet Oncology|2023Cited by 101